ClinicalTrials.gg
Active, not recruitingNCT03100149PASADENAUpdated Sep 11, 2026Results posted

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Phase 2 interventional study of RO7046015 and RO7046015 in Parkinson's Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 55 sites in 5 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
103rd of 1,256
316 · median 36
Started
2017
with 84 others
Phase 2
234 of 1,649
25 open now
Primary completion
2019-11
later than 4 of 383 live
Registered
772nd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 103rd largest by enrollment of the 1,256 interventional ones that give a count, is one of 85 that started in 2017, is one of 234 in phase 2, reaches primary completion later than 4 of the 383 other live ones, and was the 772nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic PD with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) being present, without any other known or suspected cause of PD untreated or treated with MAO-B inhibitor
  • Body weight range between: >/=45 kg/ 99 pounds (lbs) and less than or equal to (\</=) 110 kg/242 lbs
  • (BMI) of 18 to 34 kilograms per meter-squared (kg/m\^2)
  • A diagnosis of PD for 2 years or less at screening
  • Hoehn and Yahr Stage I or II
  • A screening brain DaT-SPECT consistent with PD (central reading)
  • Clinical status does not require dopaminergic PD medication and is not expected to require dopaminergic treatment within 52 weeks from baseline
  • If presently being treated for PD, a stable dose of MAO-B inhibitor (rasagiline or selegiline) for at least 90 days prior to baseline and not expected to change within 52 weeks
  • For women of : use of highly effective methods (that result in a failure rate of \<1 percent [%] per year) during the treatment period and for at least 30 days (or longer if required by local regulations) after the last dose of study drug
  • For men with female partners of childbearing potential or pregnant female partners, must use a condom during the treatment period and for at least 30 days (or longer if required by local regulations) after the last dose of study drug to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The female partners should use a contraception method with a failure rate of \<1% per year during the treatment period and for at least 30 days (or longer if required by local regulations) after the last dose of study drug. Use of contraceptive measures is not required for male participants enrolled in Part 3.

Exclusion criteria

Exclusion Criteria:

  • Medical history indicating a Parkinson syndrome other than idiopathic PD, including but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced parkinsonism, essential tremor, primary dystonia
  • Known carriers of certain familial PD genes (as specified in study protocol)
  • History of PD related freezing episodes or falls
  • A diagnosis of a significant CNS disease other than Parkinson's disease; history of repeated head injury; history of epilepsy or seizure disorder other than febrile seizures as a child
  • (MMSE) \</=25
  • Reside in a nursing home or assisted care facility
  • History of or screening brain magnetic resonance imaging (MRI) scan indicative of abnormality
  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study or interfere with the participant's ability to comply with study procedures or abide by study restrictions, or with the ability to interpret safety data
  • Any significant cardiovascular condition
  • Any significant laboratory abnormality
  • Lactating women
  • Prior treatment with dopaminergic medication (for example, levodopa or a dopaminergic agonist) with no clinical treatment response or a clinical treatment response inconsistent with PD (for example, absence of observable response to a sufficiently high-dose of levodopa [i.e., ≥ 600 mg/day])
  • Use of any of the following: catechol-O-methyl transferase (COMT) inhibitors (entacapone, tolcapone), amantadine or anticholinergics, or dopaminergic medication (levodopa and both ergot and non-ergot [pramipexole, ropinirole, rotigotine] dopamine agonists) for more than a total of 60 days or within 60 days of baseline
  • Anti-epileptic medication for non-seizure-related treatment which has not remained stable for at least 60 days prior to baseline
  • Anti-depressant or anxiolytic use that has not remained stable for at least 90 days prior to baseline. The use of fluoxetine and fluvoxamine is not permitted. For patients treated with a MAO-B inhibitor and an antidepressant (except fluoxetine and fluvoxamine), a 6-month period of stable and tolerated dosing before baseline is required.
  • Use of any of the following within 90 days prior to baseline: antipsychotics (including clozapine and olanzapine), metoclopramide, alpha methyldopa, clozapine, olanzapine, flunarizine, amoxapine, amphetamine derivatives, reserpine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, and modafinil
  • Participated in an drug, device, surgical , or stem cell study in PD
  • Any prior treatment with an investigational PD-related vaccine (including active immunization or passive immunotherapy with monoclonal antibodies).
  • Prior participation in any RO7046015 or PRX002 study
  • Receipt of any non-PD investigational product or device, or participation in a non-PD drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) before baseline
  • Receipt of any monoclonal antibody or an investigational immunomodulator within 180 days (or 5 half-lives, whichever is longer) before baseline
  • Immunomodulating drugs within 30 days prior to baseline
  • Allergy to any of the components of RO7046015 such as citrate, trehalose and polysorbate (Tween) 20 or a known or an Infusion-related reaction (IRR) to the administration of any other monoclonal antibody
  • Any to obtaining a brain MRI. Patients with a hypersensitivity to iodine may receive an alternative thyroid blocking agent.
  • For participants consenting to provide optional cerebrospinal fluid (CSF) samples by lumbar puncture (LP): LP will only be performed if the participant does not have any contraindication to undergoing an LP
  • Donation of blood over 500 milliliters (mL) within three months prior to screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    Part 1: RO7046015 High Dose

    Participants will receive RO7046015 at high dose level as intravenous (IV) infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.

    Drug: RO7046015

  • Experimental
    Part 1: RO7046015 Low Dose

    Participants will receive RO7046015 at low dose level as IV infusion Q4W up to 52 weeks in Part 1.

    Drug: RO7046015

  • Placebo comparator
    Part 1: Placebo

    Participants will receive placebo as IV infusion Q4W up to 52 weeks in Part 1.

    Drug: Placebo

  • Experimental
    Part 2: RO7046015 High Dose

    Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as IV infusion Q4W for additional 52 weeks in Part 2.

    Drug: RO7046015

  • Experimental
    Part 2: RO7046015 Low Dose

    Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as IV infusion Q4W for additional 52 weeks in Part 2.

    Drug: RO7046015

  • Experimental
    Part 3: RO7046015 Low Dose

    All participants who complete Part 1 and Part 2 will receive monthly IV infusions of RO7046015.

    Drug: RO7046015

Interventions

  • RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.

    Also known as: PRX002; prasinezumab

  • RO7046015 will be administered at dose of 1512 mg to all participants in the indicated arm.

    Also known as: PRX002; prasinezumab

  • DrugPlacebo

    RO7046015 placebo will be administered to all participants in the indicated arm.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52

    The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. The MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range: 0-236). A higher score indicated more severe symptoms of Parkinson's disease.

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Change From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores

    The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. There are 4 subscores in Part III: Bradykinesia, Rigidity, Resting tremors and Axial symptoms. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range:0-236). A higher score indicated more severe symptoms of Parkinson's disease.

    Time frame: From baseline to Week 52

  2. Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side

    DaT-SPECT (dopamine transporter imaging with single photon emission computed tomography) is a dopamine transporter SPECT imaging that uses a radioactive agent called 123\^I-ioflupane to quantify the density of the dopamine transporters in the striatum. Changes from baseline to week 52 in DaT-SPECT striatal binding ratios (SBRs; reference region: occipital cortex) in the putamen ipsilateral to the clinically most affected side were analyzed.

    Time frame: From baseline to Week 52

  3. Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score

    The Montreal Cognitive Assessment (MoCA) is a rapid screening that was developed to be more sensitive to participants presenting with mild cognitive complaints. It briefly assesses short term and working memory, visuospatial abilities, executive function, attention, concentration, language and orientation. Scores on the MoCA test range from 0-30. Higher scores are associated with better cognitive function.

    Time frame: From baseline to Week 52

  4. Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Score

    The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by CGI-I Scale grouping at week 52 was analyzed using a logistic regression model.

    Time frame: From baseline to Week 52

  5. Change From Baseline in Patient Global Impression of Change (PGIC) Score

    The PGIC was intended as a measure of change in health state from the participants perspective. PGIC scores ranged from 1 (very much improved) through to 7 (very much worse). For the PGIC, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by PGIC Scale grouping at week 52 was analyzed using a logistic regression model.

    Time frame: From baseline to Week 52

  6. Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score

    The SE-ADL is a single item scale assessing Activities of Daily Living on a scale ranging from 0% (bedridden) to 100% (completely independent), using 10% intervals.

    Time frame: From baseline to Week 52

  7. Time to Worsening in Motor or Non-Motor Symptoms

    This outcome measure is defined as the time to between first dose of study medication and the date when the particiapnt increases in MDS-UPDRS Part I (Range 0-52) of 3 or more points, or in MDS-UPDRS Part II (Range 0-52) of 3 or more points, whichever comes first. A higher score indicated more severe motor signs of Parkinson's disease.

    Time frame: From baseline to Week 52

  8. Time to Start of Dopaminergic Parkinson's Disease Treatment

    This endpoint is defined as the time between first dose of study medication and the date when the participant starts dopaminergic treatment.

    Time frame: From baseline to Week 52

  9. Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: From baseline to Week 52

  10. Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7046015

    Samples of the participant's blood was taken to evaluate anti-drug antibodies (ADA). The number of ADA positive participants, Treatment-induced and Treatment-enhanced was reported. Treatment-induced = participants with ADA negative or missing data at baseline but develop an ADA response following exposure to the study drug. Treatment-enhanced = participants with ADA positive at baseline and the titre of one or more post-baseline samples is at least \>=4 fold increase greater than the baseline titre sample.

    Time frame: Baseline, Pre-dose (0 hours) on Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

  11. Systemic Clearance (CL) of RO7046015

    Clearance is a measure of the rate at which a drug is removed from the body.

    Time frame: Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

  12. Apparent Volume of Distribution (Vz/F) of RO7046015

    Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

  13. Area Under the Serum Concentration-Time Curve (AUC) of RO7046015 Over the Dosing Interval

    AUC is defined as the measure of RO7046015 plasma concentration over time.

    Time frame: Baseline over the duration of the study

  14. Maximum Observed Serum Concentration (Cmax) of RO7046015 at Steady-state

    Cmax is the maximum observed plasma concentration of RO7046015.

    Time frame: Baseline over the duration of the study

  15. Minimum Observed Serum Concentration (Ctrough) of RO7046015 at Steady-state

    Cmin is the minimum observed plasma concentration of RO7046015.

    Time frame: Baseline over the duration of the study

07

Results

Posted Feb 8, 2021

Participant flow

Participants were enrolled at 57 sites in 5 different countries. 1 site had only 1 screen failure and no active participants were enrolled there.

Participant flow — Overall Study
MilestonePart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Started105105106
Completed105101104
Not completed042
Withdrew: Adverse event010
Withdrew: Participant moved out of country001
Withdrew: Withdrawal by subject031

Outcome measures

PrimaryChange From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52

The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. The MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range: 0-236). A higher score indicated more severe symptoms of Parkinson's disease.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52
Units on a scalePart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 529.37 ± 1.2217.35 ± 1.2258.75 ± 1.234
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.2385 · Difference in adjusted means: -2.02 · 80% CI -4.21 to 0.18
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.7169 · Difference in adjusted means: -0.62 · 80% CI -2.82 to 1.58
SecondaryChange From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores

The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. There are 4 subscores in Part III: Bradykinesia, Rigidity, Resting tremors and Axial symptoms. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range:0-236). A higher score indicated more severe symptoms of Parkinson's disease.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores
Units on a scalePart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Part IA-0.19 ± 0.119-0.27 ± 0.119-0.10 ± 0.121
Part IB0.94 ± 0.2470.90 ± 0.2480.96 ± 0.251
Part I total0.77 ± 0.2950.59 ± 0.2970.89 ± 0.300
Part II total2.75 ± 0.3733.09 ± 0.3752.69 ± 0.376
Part III total5.57 ± 0.8973.69 ± 0.9004.55 ± 0.911
Part III subscore - rigidity0.61 ± 0.2630.70 ± 0.2650.86 ± 0.268
Part III subscore - bradykinesia2.79 ± 0.5561.72 ± 0.5602.35 ± 0.565
Part III subscore - resting tremor1.20 ± 0.2310.59 ± 0.2330.79 ± 0.234
Part III subscore - axial symptoms0.19 ± 0.0770.11 ± 0.0780.18 ± 0.079
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.6116 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.08 · 80% CI -0.30 to 0.13
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.6188 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.08 · 80% CI -0.13 to 0.30
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.9062 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.04 · 80% CI -0.48 to 0.40
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.9621 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.02 · 80% CI -0.43 to 0.46
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.6510 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.19 · 80% CI -0.71 to 0.34
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.7709 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.12 · 80% CI -0.41 to 0.65
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.5177 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.34 · 80% CI -0.33 to 1.01
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.9095 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.06 · 80% CI -0.73 to 0.61
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.1354 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -1.88 · 80% CI -3.49 to -0.27
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.4217 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -1.02 · 80% CI -2.64 to 0.61
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.8053 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.09 · 80% CI -0.38 to 0.56
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.4970 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.25 · 80% CI -0.22 to 0.73
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.1703 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -1.07 · 80% CI -2.07 to -0.07
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.5729 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.44 · 80% CI -1.45 to 0.56
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.0628 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.61 · 80% CI -1.02 to -0.19
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.2125 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.41 · 80% CI -0.82 to 0.01
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Mixed Models Analysis · p = 0.4577 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.08 · 80% CI -0.22 to 0.06
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Mixed Models Analysis · p = 0.9182 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.01 · 80% CI -0.15 to 0.13
SecondaryChange From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side

DaT-SPECT (dopamine transporter imaging with single photon emission computed tomography) is a dopamine transporter SPECT imaging that uses a radioactive agent called 123\^I-ioflupane to quantify the density of the dopamine transporters in the striatum. Changes from baseline to week 52 in DaT-SPECT striatal binding ratios (SBRs; reference region: occipital cortex) in the putamen ipsilateral to the clinically most affected side were analyzed.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Striatal Binding Ratio (SBR)
Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side
Striatal Binding Ratio (SBR)Part 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side-0.08 ± 0.018-0.10 ± 0.018-0.11 ± 0.018
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · ANCOVA · p = 0.3582 (Nominal p-values are displayed for descriptive purposes only.) · Ls means difference: -0.02 · 80% CI -0.05 to 0.01
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · ANCOVA · p = 0.1955 (Nominal p-values are displayed for descriptive purposes only.) · Ls means difference: -0.03 · 80% CI -0.06 to 0.00
SecondaryChange From Baseline in Montreal Cognition Assessment (MoCA) Total Score

The Montreal Cognitive Assessment (MoCA) is a rapid screening that was developed to be more sensitive to participants presenting with mild cognitive complaints. It briefly assesses short term and working memory, visuospatial abilities, executive function, attention, concentration, language and orientation. Scores on the MoCA test range from 0-30. Higher scores are associated with better cognitive function.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score
Units on a scalePart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score0.07 ± 0.1770.30 ± 0.1810.51 ± 0.178
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · ANCOVA · p = 0.3611 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.22 · 80% CI -0.09 to 0.54
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · ANCOVA · p = 0.0727 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: 0.44 · 80% CI 0.13 to 0.75
SecondaryChange From Baseline in Clinical Global Impression of Improvement (CGI-I) Score

The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by CGI-I Scale grouping at week 52 was analyzed using a logistic regression model.

Time frame:
From baseline to Week 52
Reported as:
Number · Percentage of participants
Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Score
Percentage of participantsPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Progressors56.650.048.6
Responders43.450.051.4
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Regression, Logistic · p = 0.4265 (Nominal p-values are displayed for descriptive purposes only.) · Odds ratio (or): 0.77 · 80% CI 0.50 to 1.18
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Regression, Logistic · p = 0.4063 (Nominal p-values are displayed for descriptive purposes only.) · Odds ratio (or): 0.76 · 80% CI 0.49 to 1.16
SecondaryChange From Baseline in Patient Global Impression of Change (PGIC) Score

The PGIC was intended as a measure of change in health state from the participants perspective. PGIC scores ranged from 1 (very much improved) through to 7 (very much worse). For the PGIC, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by PGIC Scale grouping at week 52 was analyzed using a logistic regression model.

Time frame:
From baseline to Week 52
Reported as:
Number · Percentage of participants
Change From Baseline in Patient Global Impression of Change (PGIC) Score
Percentage of participantsPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Progressors58.150.753.5
Responders41.949.346.5
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Regression, Logistic · p = 0.3847 (Nominal p-values are displayed for descriptive purposes only.) · Odds ratio (or): 0.75 · 80% CI 0.48 to 1.15
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Regression, Logistic · p = 0.7055 (Nominal p-values are displayed for descriptive purposes only.) · Odds ratio (or): 0.88 · 80% CI 0.57 to 1.36
SecondaryChange From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score

The SE-ADL is a single item scale assessing Activities of Daily Living on a scale ranging from 0% (bedridden) to 100% (completely independent), using 10% intervals.

Time frame:
From baseline to Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score
Units on a scalePart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score-1.83 ± 0.644-2.56 ± 0.650-2.50 ± 0.647
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · ANCOVA · p = 0.4142 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.73 · 80% CI -1.87 to 0.41
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · ANCOVA · p = 0.4486 (Nominal p-values are displayed for descriptive purposes only.) · Difference in adjusted means: -0.67 · 80% CI -1.81 to 0.47
SecondaryTime to Worsening in Motor or Non-Motor Symptoms

This outcome measure is defined as the time to between first dose of study medication and the date when the particiapnt increases in MDS-UPDRS Part I (Range 0-52) of 3 or more points, or in MDS-UPDRS Part II (Range 0-52) of 3 or more points, whichever comes first. A higher score indicated more severe motor signs of Parkinson's disease.

Time frame:
From baseline to Week 52
Reported as:
Median · Days
Time to Worsening in Motor or Non-Motor Symptoms
DaysPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Time to Worsening in Motor or Non-Motor Symptoms174.0 (168.0 to 225.0)169.0 (117.0 to 173.0)170.0 (168.0 to 222.0)
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Regression, Cox · p = 0.3769 (Nominal p-values are displayed for descriptive purposes only.) · Hazard ratio (hr): 1.15 · 80% CI 0.94 to 1.42
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Regression, Cox · p = 0.1658 (Nominal p-values are displayed for descriptive purposes only.) · Hazard ratio (hr): 1.25 · 80% CI 1.02 to 1.53
SecondaryTime to Start of Dopaminergic Parkinson's Disease Treatment

This endpoint is defined as the time between first dose of study medication and the date when the participant starts dopaminergic treatment.

Time frame:
From baseline to Week 52
Reported as:
Median · Days
Time to Start of Dopaminergic Parkinson's Disease Treatment
DaysPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Time to Start of Dopaminergic Parkinson's Disease TreatmentNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Part 1: Placebo vs Part 1: RO7046015 Low Dose · Regression, Cox · p = 0.9542 (Nominal p-values are displayed for descriptive purposes only.) · Hazard ratio (hr): 1.01 · 80% CI 0.77 to 1.33
  • Part 1: Placebo vs Part 1: RO7046015 High Dose · Regression, Cox · p = 0.4567 (Nominal p-values are displayed for descriptive purposes only.) · Hazard ratio (hr): 0.84 · 80% CI 0.63 to 1.13
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
From baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Percentage of participantsPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
AEs82.993.391.5
SAEs4.86.77.5
SecondaryPercentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7046015

Samples of the participant's blood was taken to evaluate anti-drug antibodies (ADA). The number of ADA positive participants, Treatment-induced and Treatment-enhanced was reported. Treatment-induced = participants with ADA negative or missing data at baseline but develop an ADA response following exposure to the study drug. Treatment-enhanced = participants with ADA positive at baseline and the titre of one or more post-baseline samples is at least \>=4 fold increase greater than the baseline titre sample.

Time frame:
Baseline, Pre-dose (0 hours) on Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

Results for this outcome have not been posted.

SecondarySystemic Clearance (CL) of RO7046015

Clearance is a measure of the rate at which a drug is removed from the body.

Time frame:
Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

Results for this outcome have not been posted.

SecondaryApparent Volume of Distribution (Vz/F) of RO7046015

Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)

Results for this outcome have not been posted.

SecondaryArea Under the Serum Concentration-Time Curve (AUC) of RO7046015 Over the Dosing Interval

AUC is defined as the measure of RO7046015 plasma concentration over time.

Time frame:
Baseline over the duration of the study

Results for this outcome have not been posted.

SecondaryMaximum Observed Serum Concentration (Cmax) of RO7046015 at Steady-state

Cmax is the maximum observed plasma concentration of RO7046015.

Time frame:
Baseline over the duration of the study

Results for this outcome have not been posted.

SecondaryMinimum Observed Serum Concentration (Ctrough) of RO7046015 at Steady-state

Cmin is the minimum observed plasma concentration of RO7046015.

Time frame:
Baseline over the duration of the study

Results for this outcome have not been posted.

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/105 (0%)5/105 (4.8%)57/105 (54.3%)
Part 1: RO7046015 Low Dose0/105 (0%)7/105 (6.7%)67/105 (63.8%)
Part 1: RO7046015 High Dose0/106 (0%)8/106 (7.5%)69/106 (65.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Infusion related reactionInjury, poisoning and procedural complications0/1050/1052/106
Acute myocardial infarctionCardiac disorders1/1050/1050/106
Cardiac failureCardiac disorders0/1051/1050/106
Inguinal herniaGastrointestinal disorders1/1050/1050/106
Influenza like illnessGeneral disorders0/1051/1050/106
Radius fractureInjury, poisoning and procedural complications1/1050/1050/106
Ulna fractureInjury, poisoning and procedural complications1/1050/1050/106
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1051/1051/106
Ligament disorderMusculoskeletal and connective tissue disorders1/1050/1050/106
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1051/1050/106
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPart 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High Dose
Infusion related reactionInjury, poisoning and procedural complications17/10520/10535/106
NasopharyngitisInfections and infestations15/10520/10513/106
HeadacheNervous system disorders10/10510/10512/106
Back painMusculoskeletal and connective tissue disorders8/1058/10511/106
ConstipationGastrointestinal disorders6/1058/10510/106
FallInjury, poisoning and procedural complications5/1055/10510/106
NauseaGastrointestinal disorders9/1055/1059/106
Upper respiratory tract infectionInfections and infestations9/1054/1059/106
ArthralgiaMusculoskeletal and connective tissue disorders8/1057/1054/106
InsomniaPsychiatric disorders5/1053/1058/106

Baseline characteristics

The modified intent-to-treat (mITT) population includes all participants randomized in the study who received any amount of study drug treatment.

Age, Continuous
Age, Continuous(Years)Part 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High DoseTotal
Mean59.9 ± 8.760.3 ± 8.859.4 ± 9.859.9 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High DoseTotal
Female343435103
Male717171213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PlaceboPart 1: RO7046015 Low DosePart 1: RO7046015 High DoseTotal
Asian1001
Black or African American0202
White918389263
Unknown13201750
08

Study locations

55 sites
09

References and documents

Publications

  • Coles D, Kalyana A, Khalil S, Chauhan D, Rupasinghe T, Costello C, Batla A, Young T. The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review. Parkinsons Dis. 2026 Jul 22;2026:8540084. doi: 10.1155/padi/8540084. eCollection 2026. PubMed 42495570 ↗
  • Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. PubMed 40523921 ↗
  • Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, Brockmann K, Smigorski K, Gerbaldo V, Fontoura P, Doody R, Kerchner GA, Brundin P, Marek K, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec;30(12):3669-3675. doi: 10.1038/s41591-024-03270-6. Epub 2024 Oct 8. PubMed 39379705 ↗
  • Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, Lopez-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga S, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. PubMed 35921451 ↗
  • Lipsmeier F, Taylor KI, Postuma RB, Volkova-Volkmar E, Kilchenmann T, Mollenhauer B, Bamdadian A, Popp WL, Cheng WY, Zhang YP, Wolf D, Schjodt-Eriksen J, Boulay A, Svoboda H, Zago W, Pagano G, Lindemann M. Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease. Sci Rep. 2022 Jul 15;12(1):12081. doi: 10.1038/s41598-022-15874-4. PubMed 35840753 ↗
  • Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. PubMed 34659081 ↗
  • Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487. PubMed 29913017 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Nov 2019, 29 months.

Results were first posted in Feb 2021, 1 year 2 months after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 29 months is above that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2017
First posted
Apr 4, 2017
StartActual
Jun 27, 2017
Primary completionActual
Nov 27, 2019
CompletionEst.
Dec 1, 2031
Results first posted
Feb 8, 2021
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03100149
Lead sponsor
Hoffmann-La Roche
Collaborators
Prothena Biosciences Limited
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Jun 27, 2017
Primary completion
Nov 27, 2019
Completion
Dec 1, 2031 (estimated)
Results posted
Feb 8, 2021
Last update
Sep 11, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prasinezumab

Start the discussion